The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preclinical characterization of HBW-012-E, a novel, potent, selective, safe, and orally active KRAS G12D inhibitor with superior pharmacokinetic (PK) properties and anti-tumor efficacy.
 
Ning Lee
Employment - Hyperway Pharmaceuticals
Leadership - Hyperway Pharmaceuticals
Stock and Other Ownership Interests - Hyperway Pharmaceuticals
 
Yingfu Li
Employment - Hyperway Pharmaceuticals
Leadership - Hyperway Pharmaceuticals
Stock and Other Ownership Interests - Hyperway Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Hyperway Pharmaceuticals
 
Guanfeng Liu
Employment - Hyperway Pharmaceuticals
Leadership - Hyperway Pharmaceuticals
Stock and Other Ownership Interests - Hyperway Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Hyperway Pharmaceuticals
 
Jiang Li
Employment - Hyperway Pharmaceuticals
Leadership - Hyperway Pharmaceuticals
Stock and Other Ownership Interests - Hyperway Pharmaceuticals
 
Junfeng Ren
Employment - Hyperway Pharmaceuticals
Leadership - Hyperway Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Hyperway Pharmaceuticals